201 related articles for article (PubMed ID: 12908755)
21. [Analysis of the proliferative potential of meningiomas with MIB-1 monoclonal antibodies].
Miyagami M; Shibuya T; Miyagi A; Tsubokawa T
No To Shinkei; 1996 Jan; 48(1):39-43. PubMed ID: 8679317
[TBL] [Abstract][Full Text] [Related]
22. Proliferating cell nuclear antigen (PCNA) in atypical and malignant meningiomas.
Zimmer C; Gottschalk J; Cervos-Navarro J; Martin H; Beil M; Jautzke G
Pathol Res Pract; 1992 Dec; 188(8):951-8. PubMed ID: 1363764
[TBL] [Abstract][Full Text] [Related]
23. [Proliferative markers of meningiomas: immunohistochemical analysis and prognostic value].
Korshunov AG; Shishkina LV; Golanov AV
Arkh Patol; 2002; 64(1):29-33. PubMed ID: 11889696
[TBL] [Abstract][Full Text] [Related]
24. MIB-1 immunostaining and DNA flow cytometry in meningiomas.
Yasue M; Akasaki Y; Numoto TR; Abe S; Abe T; Takeuchi Y; Tanaka J
Noshuyo Byori; 1996 Apr; 13(1):17-20. PubMed ID: 8916122
[TBL] [Abstract][Full Text] [Related]
25. Clinico-pathological correlations in meningiomas: a DNA and immunohistochemical study.
Cruz-Sánchez FF; Miquel R; Rossi ML; Figols J; Palacín A; Cardesa A
Histol Histopathol; 1993 Jan; 8(1):1-8. PubMed ID: 8443419
[TBL] [Abstract][Full Text] [Related]
26. Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas.
Bozkurt SU; Ayan E; Bolukbasi F; Elmaci I; Pamir N; Sav A
APMIS; 2009 Sep; 117(9):651-9. PubMed ID: 19703125
[TBL] [Abstract][Full Text] [Related]
27. Detection of S100B, S100A6 and galectin-3 ligands in meningiomas as markers of aggressiveness.
Hancq S; Salmon I; Brotchi J; Gabius HJ; Heizmann CW; Kiss R; Decaestecker C
Int J Oncol; 2004 Nov; 25(5):1233-40. PubMed ID: 15492810
[TBL] [Abstract][Full Text] [Related]
28. Correlation between histological grade and MIB-1 and p53 immunoreactivity in meningiomas.
Ozen O; Demirhan B; Altinörs N
Clin Neuropathol; 2005; 24(5):219-24. PubMed ID: 16167545
[TBL] [Abstract][Full Text] [Related]
29. Recurrence of meningiomas versus proliferating cell nuclear antigen (PCNA) positivity and AgNOR counting.
Demirtaş E; Yilmaz F; Ovül I; Oner K
Acta Neurochir (Wien); 1996; 138(12):1456-63. PubMed ID: 9030354
[TBL] [Abstract][Full Text] [Related]
30. MIB-1 immunolabeling: a valuable marker in prediction of benign recurring meningiomas.
Vankalakunti M; Vasishta RK; Das Radotra B; Khosla VK
Neuropathology; 2007 Oct; 27(5):407-12. PubMed ID: 18018472
[TBL] [Abstract][Full Text] [Related]
31. Triple approach for diagnosis and grading of meningiomas: histology, morphometry of Ki-67/Feulgen stainings, and cytogenetics.
Kolles H; Niedermayer I; Schmitt C; Henn W; Feld R; Steudel WI; Zang KD; Feiden W
Acta Neurochir (Wien); 1995; 137(3-4):174-81. PubMed ID: 8789658
[TBL] [Abstract][Full Text] [Related]
32. Cytogenetic and proliferative potentials in meningiomas.
Debiec-Rychter M; Biernat W; Limon J; Kordek R; Izycka E; Borowska-Lehman J; Imieliński B; Liberski PP
Pol J Pathol; 1999; 50(4):243-8. PubMed ID: 10721264
[TBL] [Abstract][Full Text] [Related]
33. Primary resected meningiomas: relapses and proliferation markers.
Kalala JP; Caemaert J; De Ridder L
In Vivo; 2004; 18(4):411-6. PubMed ID: 15369177
[TBL] [Abstract][Full Text] [Related]
34. DNA topoisomerase IIalpha expression correlates with cell proliferation but not with recurrence in intracranial meningiomas.
Konstantinidou AE; Patsouris E; Korkolopoulou P; Kavantzas N; Mahera H; Davaris P
Histopathology; 2001 Oct; 39(4):402-8. PubMed ID: 11683942
[TBL] [Abstract][Full Text] [Related]
35. Anaplastic secretory meningioma: a case report.
Ferchichi L; Bellil S; Ben Hammouda K; Bellil K; Mekni A; Bettaieb I; Haouet S; Khaldi MM; Zitouna K; Kchir N
Pathologica; 2006 Apr; 98(2):153-5. PubMed ID: 16929789
[TBL] [Abstract][Full Text] [Related]
36. [Ag-NORs, nucleus-nucleolus-associated antigens (Ki67, PCNA, P-105 and p-120): prognostic markers of meningioma recurrence].
Crafa P; Campanini N; Martella EM; Trabattoni G; Tedeschi F
Acta Biomed Ateneo Parmense; 1994; 65(5-6):297-308. PubMed ID: 8592922
[TBL] [Abstract][Full Text] [Related]
37. Nucleolar organizer regions in meningiomas. Correlation with histopathologic malignancy grading, DNA cytometry and clinical outcome.
Plate KH; Ruschoff J; Mennel HD
Anal Quant Cytol Histol; 1990 Dec; 12(6):429-38. PubMed ID: 2078265
[TBL] [Abstract][Full Text] [Related]
38. Correlation of histopathologic classification with proliferative activity and DNA ploidy in 120 intracranial meningiomas, with special reference to atypical meningioma.
Myong NH; Chi JG
J Korean Med Sci; 1997 Jun; 12(3):221-7. PubMed ID: 9250918
[TBL] [Abstract][Full Text] [Related]
39. Ki-67 immunoreactivity in meningiomas--determination of the proliferative potential of meningiomas using the monoclonal antibody Ki-67.
Madsen C; Schrøder HD
Clin Neuropathol; 1997; 16(3):137-42. PubMed ID: 9197938
[TBL] [Abstract][Full Text] [Related]
40. Expression of PDGF and its receptor as well as their relationship to proliferating activity and apoptosis of meningiomas in human meningiomas.
Yang SY; Xu GM
J Clin Neurosci; 2001 May; 8 Suppl 1():49-53. PubMed ID: 11386826
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
